Morgan Stanley Maintains Overweight on Legend Biotech, Lowers Price Target to $43

Benzinga · 1d ago
Morgan Stanley analyst Matthew Harrison maintains Legend Biotech (NASDAQ:LEGN) with a Overweight and lowers the price target from $49 to $43.